視床下部性肥満 - パイプラインアナリティクス：2023年

当レポートでは、視床下部性肥満のパイプラインについて調査し、第1相、第2相、第3相のパイプライン動向、市場における競合情勢、法規制動向、パイプラインの薬剤プロファイルなどをまとめています。

目次

概要

視床下部性肥満の標的

• イントロダクション
• 視床下部性肥満の疫学と原因
• 視床下部性肥満の病態生理学
• 視床下部性肥満の治療アプローチ
• 治療アルゴリズム

視床下部性肥満の段階別パイプライン分析

• 視床下部性肥満の発症- 概要
• パイプライン製品、開発段階別
• 視床下部性肥満の競合情勢、相別
• パイプライン製品、企業別
• 視床下部性肥満の単剤療法と併用療法の臨床試験
• パイプライン製品、作用機序別
• 視床下部性肥満の臨床および規制スケジュール
• 後期段階のプロファイルの比較の概要

視床下部性肥満症のライセンシング、買収、およびコラボレーション契約

視床下部性肥満パイプラインの情勢

• 視床下部性肥満パイプラインの薬剤プロファイル

第Ⅲ相

• セトメラノチド（Rhythm Pharmaceuticals）
• エクセナチド（AstraZeneca）

第II相

• テソメット（Saniona）

第I相

• GT-001（Gila Therapeutics, Inc）

前臨床

• ENT-03（Enterin Inc）
• TRP-8802（Tryp Therapeutics）

視床下部性肥満におけるSWOT分析

付録

The Hypothalamic Obesity report covers the Hypothalamic Obesity market opportunity providing Key Competitive Analysis, 6 Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. In addition, our report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, mechanism of action, intervention types. The Hypothalamic Obesity report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Hypothalamic obesity (HyOb) is a complex medical condition that can arise from the development of rare brain tumors or other forms of hypothalamic injury. Among the tumors that can give rise to HyOb, craniopharyngioma is a noteworthy example. Hypothalamic obesity is characterized by an abnormal hypothalamus function, a key aspect of which is its involvement in satiety and food intake regulation. Notably, damage to the ventromedial nucleus of the hypothalamus bilaterally can lead to a syndrome of HyOb that is typified by hyperphagia and obesity, as well as other endocrinal and neurological manifestations.

In this report, Mellalta Meets provides an in-depth analysis of Hypothalamic Obesity pipeline covering Phase III , Phase II & Phase I Pipeline Analysis Overview, Pipeline Products by Stage of Development, Hypothalamic Obesity Competitive Landscape Distinguished by Phase & Route and moleucle type, Clinical Pipeline Products by Company, Hypothalamic Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Hypothalamic Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are 6 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are AstraZeneca, Rhythm Pharmaceuticals, Saniona, Gila Therapeutics, which have robust clinical pipelines of Hypothalamic Obesity candidates.

As per analysis, the development pipeline is full of molecules like small molecules, and peptides.

Key Highlights of the Hypothalamic Obesity Report

• The Hypothalamic Obesity segment is dominated by the Phase 3 and pre-clinical assets (XX each) which represent XX% of the total development followed by XX each asset in Phase 1 and Phase 2 representing XX% of each of the pipeline development in Hypothalamic Obesity.

• The hypothalamic obesity treatment pipeline is marked by a strong presence of US-based biotech companies, accounting for an impressive XX% of all clinical-stage hypothalamic obesity therapies, followed by UK, Canada and Denmark with XX%.

• Hypothalamic Obesity pipeline landscape includes 100% of Monotherapy trials.

• The Hypothalamic Obesity segment is split equally between the pre-clinical and Phase 3 assets (2-2 each), phase 1 assets (2), and Phase 2 assets (2).

Report Coverage:

• Indication Prioritisation: Hypothalamic Obesity market potential based on Indications.

• Business Transactions & Strategies: Key collaborations and deal values

• Hypothalamic Obesity Pipeline Development: Product Profiles, Clinical Trials & Results

• Hypothalamic Obesity Acquisition Targets

• Hypothalamic Obesity Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The Hypothalamic Obesity Target BACKGROUND

• Introduction
• Epidemiology & Causes of hypothalamic obesity
• Pathophysiology of Hypothalamic Obesity
• Treatment Approach of Hypothalamic Obesity
• Treatment Algorithm

Hypothalamic Obesity PIPELINE ANALYSIS by Phases

• Hypothalamic Obesity Development - Overview
• Pipeline Products by Stage of Development
• Hypothalamic Obesity Competitive Landscape by Phases
• Pipeline Products by Company
• Hypothalamic Obesity Monotherapy & Combinations Clinical Trials
• Pipeline Products by MOA
• Hypothalamic Obesity Clinical & Regulatory Timelines
• Late-Stage Profiles Comparisons At-a-glance

Hypothalamic Obesity LICENSING, ACQUISITION, AND COLLABORATION DEALS

• Hypothalamic Obesity Licensing, Acquisition, and Deal values
• Hypothalamic Obesity Licensing by Transaction type and total amount size by Phases

Hypothalamic Obesity Pipeline Landscape

• Hypothalamic Obesity Pipeline Drug Profiles

Phase III

• Setmelanotide (Rhythm Pharmaceuticals)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Exenatide (AstraZeneca)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase II

• Tesomet (Saniona)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase I

• GT-001 (Gila Therapeutics, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Preclinical

• ENT-03 (Enterin Inc.)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• TRP-8802 (Tryp Therapeutics)
  • Product Profile & Description
  • Collaborations
  • Other Developments

Hypothalamic Obesity SWOT Analysis

Appendix

• About us